Analysis of blood biomarkers in cancer patients
Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4
This study is testing how blood samples from cancer patients can help doctors better understand and treat their cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 2050 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut Curie Academic / other |
| Locations | 2 sites (Paris and 1 other locations) |
| Trial ID | NCT05088395 on ClinicalTrials.gov |
What this trial studies
The ALCINA 4 study is a prospective biological cohort study that focuses on analyzing circulating tumor biomarkers obtained through blood sampling from cancer patients. Participants will provide up to four blood samples over a period of 12 to 18 months, with the timing varying based on the specific cohort and clinical context. The study aims to explore various biomarkers, including circulating tumor cells and circulating tumor DNA, to enhance cancer diagnosis, prognosis, and treatment efficacy. Additionally, it may involve tumor biopsies if necessary for comparison with blood samples.
Who should consider this trial
Good fit: Ideal candidates for this study are adult cancer patients who are being treated at one of the participating centers.
Not a fit: Patients who are pregnant or breastfeeding may not benefit from this study due to specific cohort requirements.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and treatment strategies for cancer patients through the use of blood-based biomarkers.
How similar studies have performed: Other studies have shown promise in using circulating biomarkers for cancer diagnosis and treatment monitoring, indicating that this approach is gaining traction in the field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient treated for cancer at one of the participating center * 18 years old or higher * Signed informed consent form * Patient not deprived of their liberty or under guardianship (including temporary guardianship) * Patient covered by social security scheme * Patient with no compliance issue (related to geographical, social or psychological reasons) for study follow up * Other additional criteria will be defined (defining tumor type and clinical setting), by cohort If a biopsy tumor sample is to be taken: * Tumor considered as accessible by biopsy (at the investigator's discretion). * Normal blood coagulation tests (if applicable, and in case of a non-superficial tumor lesion). * No anticoagulant or antiaggregant treatment for the biopsy. Exclusion Criteria : Pregnant and/or breast-feeding women depending on cohort.
Where this trial is running
Paris and 1 other locations
- Institut Curie — Paris, France (Recruiting)
- Institut Curie — Saint-Cloud, France (Recruiting)
Study contacts
- Principal investigator: Francois-Clement BIDARD — Institut Curie
- Study coordinator: Marie-Emmanuelle LEGRIER
- Email: drci.promotion@curie.fr
- Phone: 0033156245649
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.